Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 12, 2017 (9 years ago)

Gaviscon (Alumina & Magnesium Trisilicate)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Superpotent Drug: high out-of-specification result for magnesium.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Affected NDC 0088-1175-47

Compare with the code on your package — it is the most precise check available.

Drug: Magnesium

Recalling firm
Sanofi-Aventis U.S. LLC
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0926-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Magnesium recalls

See all
Class I · High risk

Magnesium Sulfate in Water for Injection

Product mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.

Ongoing Labeling / mix-up Amneal Pharmaceuticals, LLC NDC 70121-1720-3 D-0478-2026

Other recalls by Sanofi-Aventis U.S. LLC

All 2017 recalls
Class II · Moderate risk

Admelog

Lack of Assurance of Sterility: Malformed crimped collar seal

Ongoing Sterility / contamination Sanofi-Aventis U.S. LLC NDC 0024-5926-05 D-0575-2023
Class II · Moderate risk

Elitek (rasburicase)

Failed Stability Specifications: Out of Specification result for enzyme activity levels noted during routine stability testing.

Ongoing Stability / shelf life Sanofi-Aventis U.S. LLC NDC 0024-5151-75 D-1507-2020
Class II · Moderate risk

Zantac 75 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Ongoing Nitrosamine impurity Sanofi-Aventis U.S. LLC D-0545-2020
Class II · Moderate risk

Zantac 150 mg

CGMP Deviations: Presence of NDMA impurity detected in product.

Ongoing Nitrosamine impurity Sanofi-Aventis U.S. LLC D-0544-2020